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Abstract
Background: Human cytomegalovirus (HCMV) infection has been recently associated with a low risk of multiple
sclerosis (MS), yet the basis behind this observation remains uncertain. In this study, we aimed to determine in MS
patients whether HCMV induces modifications in the peripheral B cell compartment.
Methods: HCMV serostatus was determined in 73 MS patients (55 relapsing-remitting MS (RRMS); 18 progressive
MS (PMS)) and 30 healthy controls, assessing their B cell immunophenotype and cytokine production (GM-CSF, IL-6,
IL-10, and TNFα) by flow cytometry.
Results: HCMV seropositivity in untreated MS patients (n = 45) was associated with reduced switched memory B
cells, contrasting with an opposite effect in PMS. Expansions of transitional B cells were observed in HCMV(+) IFNβ-
treated RRMS patients but not in HCMV(−) cases (p < 0.01), suggesting that HCMV may influence the distribution of
B cell subsets modulating the effects of IFNβ. Considering the B cell functional profile, HCMV(−) PMS displayed an
increased secretion of proinflammatory cytokines (IL-6, TNFα) as compared to HCMV(+) PMS and RRMS cases (p < 0.001).
Conclusions: Our study reveals an influence of HCMV infection on the phenotype and function of B cells, promoting
early differentiation stages in RRMS and reducing the proinflammatory cytokine profile in advanced MS forms, which
might be related with the putative protective role of this virus in MS.
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Introduction
Multiple sclerosis (MS) is a demyelinating disease of the
central nervous system classically considered to be medi-
ated by T cells. A relevant role of B cells in MS pathogen-
esis is supported by a growing body of evidences,
particularly the successful therapeutic results using anti-
CD20 monoclonal antibodies [1, 2]. Epstein-Barr virus
(EBV), the main pathogen related to MS [3], establishes a
persistent infection having memory B cells as the main
reservoir. In this regard, it is conceivable that efficacy of
anti-CD20 therapies might depend not only on suppres-
sion of B cell functions, but also on the control of EBV in-
fection [4]. On the other hand, human cytomegalovirus
(HCMV) has been associated with a lower MS susceptibil-
ity based on seroepidemiological studies [5, 6], yet the
basis for these observations remains poorly understood.
HCMV chronic infection leads to marked changes in
the immune system [7], mainly characterized by the dif-
ferentiation and expansion of specific T cells [8] and
adaptive NK cell subsets expressing the CD94/NKG2C
activating receptor [9], a phenotypic feature that has
been associated with reduced MS progression [10]. In
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this study, we evaluated whether HCMV may have an
influence on the B cell compartment in MS patients ac-
cording to clinical features of the disease.
Methods
Samples
Blood was collected from healthy controls (HC) and MS
patients fulfilling McDonald criteria 2017 at the Neur-
ology Department, Hospital del Mar, Barcelona (Spain),
excluding cases with relapses or corticosteroid treatment
in the previous 30 days, severe concomitant disease,
pregnancy, and disease-modifying therapies known to
deplete peripheral lymphocytes or alter their trafficking.
MS forms were defined as relapsing-remitting MS
(RRMS) and progressive MS (PMS) [11].
Herpesvirus serostatus
Standard serological diagnostic tests were performed to
evaluate EBV-(LIASON®) and HCMV-specific antibodies
(Roche®, Cobas602).
B cell immunophenotype
Peripheral blood mononuclear cells (PBMCs) isolated
from blood samples using Ficoll-Hypaque density gradient
centrifugation were analyzed by flow cytometry using a
direct staining (Fig. 1) with the following fluorochrome-
conjugated monoclonal antibodies: CD19-PE-Cy7 (Invi-
trogen), CD38-APC, CD27-PerCP-Cy5.5 (BD Biosciences),
IgD-FITC (Southern Biotech), CD10-PE (Biolegend), and
DAPI (Thermo Fisher). B cell subsets were defined gating
CD19+ lymphocytes as follows: plasmablasts-plasma cells
(PB-PC: CD38hiCD10−), transitional (TB: CD38hiCD10+),
naive (NB: CD38low/negCD10−IgD + CD27−), unswitched
memory (UMB: CD38low/negCD10-IgD + CD27+),
switched memory (SMB: CD38low/negCD10−IgD−CD27+),
and double negative (DN: CD38low/negCD10−IgD−CD27
−). Samples were analyzed in LSR II Fortessa (BD Biosci-
ences) using FlowJo (Tree Star) software.
Functional analysis of B cells
B cell cytokine production was evaluated in MS patients
(RRMS, n = 45; PMS, n = 18) and HC (n = 20) incubat-
ing PBMCs for 24 h with CpG (10 μg/ml), adding in the
last 4 h PMA (50 ng/mL) and ionomycin (1 μg/ml,
Sigma-Aldrich), monensin (GolgiStop), and brefeldin
(GolgiPlug, BD Biosciences). Samples were stained using
CD19-PE-Cy7 (Invitrogen) and CD3-perCP (BD Biosci-
ences), permeabilized, fixed, and stained with the follow-
ing cytokine-specific monoclonal antibodies: anti-GM-
CSF-APC, anti-IL-6-FITC (Biolegend), anti-IL-10-PE
(BD Biosciences), and anti-TNFα conjugated with the
CFP fluorochrome. Samples were acquired in LSR II
Fortessa and data analyzed by FlowJo software, defining
the proportions of B cells stained for specific cytokines.
Statistical analysis
Kolmogorov-Smirnov test assessed normal distribution,
providing means and standard deviations for parametric
variables, and medians and interquartile range for non-
parametric variables. Values were compared using Stu-
dent’s t test for parametric variables or Mann-Whitney U
test for non-parametric, respectively. Pearson or Spear-
man correlation indexes were calculated for pair-wise con-
tinuous variables. Results were considered significant at
the two-sided level of 0.05. Data analysis was performed
using GraphPad Prism 6.0 software (La Jolla, CA).
Results
Demographic description
We studied 30 HC and 73 MS patients (55 RRMS, 18
PMS: 8 secondary PMS, 10 primary PMS) (Table 1).
HCMV serology distribution was comparable in controls
and MS patients. No HCMV-related clinical differences
were perceived, other than a lower disability score in
HCMV(+) PMS as compared to HCMV(−) PMS patients
(MSSS, 5.09 ± 2.23 vs.7.48 ± 1.28, p < 0.05).
Distribution of B cell subsets in untreated MS according
to clinical forms and HCMV serology
Assessment of the B cell immunophenotype in MS pa-
tients without treatment (n = 45) and in HC did not show
significant differences in the distribution of the main B cell
subsets (Additional file 1: Table 1). However, stratifying
MS cases according to clinical form revealed that RRMS
displayed lower proportions of TB cells together with in-
creased SMB cells as compared to HC and PMS, whereas
PMS had lower proportions of UMB (Fig. 2a). Interest-
ingly, HCMV seropositivity was associated with greater
proportions of NB and reduced SMB cells in RRMS, con-
trasting with an opposite effect in PMS (Fig. 2b). No dif-
ferences in the proportions of the different subsets were
noticed in HC stratified according to HCMV serology.
These results suggest that HCMV infection may differ-
ently influence the B cell compartment distribution in MS
depending on the clinical form.
Impact of HCMV on the B cell compartment in IFNβ-
treated MS patients
IFNβ therapy in RRMS patients (n = 23) was associated
with increased proportions of TB and NB cells, and a re-
ciprocal reduction of UMB, SMB, and DN cells (Fig. 3a),
in line with previous studies describing an effect of this
cytokine on the redistribution of B cell subsets in MS pa-
tients [12]. Glatiramer acetate treatment (n = 5) was not
associated with modifications in B cell subsets (Fig. 3a).
Remarkably, the effect of IFNβ therapy on the propor-
tions of TB cells differed according to HCMV serostatus,
observing an increase in treated HCMV(+) MS patients
but not in seronegative cases (Fig. 3b). Moreover, IFNβ
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therapy in HCMV(−) RRMS was associated with in-
creased NB and reduced SMB cells, resembling the effect
of HCMV infection on these B cell subsets described
above, which dampened the differences with HCMV(+)
treated cases (Fig. 3b). These results revealed that
HCMV infection may influence the distribution of B cell
subsets in MS patients modulating the effects of IFNβ.
Functional implications of HCMV on the cytokine profile
of B cells in MS
B cell cytokine production was evaluated as described in
the “Methods” section (Fig. 4a). No differences were
found between HC and the whole group of MS patients,
though we observed a greater IL-10 secretion by B cells
from RRMS and PMS patients as compared to HC, and
increased GM-CSF by B cells from PMS as compared to
RRMS patients (Fig. 4b). Considering B cell subsets, IL-
10 production in MS was directly related to proportions
of TB cells (R 0.35, p < 0.05) and inversely to SMB cells
(R − 0.39, p < 0.05), whereas TNFα appeared inversely
related to TB (R − 0.43, p < 0.01) and directly to UMB
(R 0.49, p < 0.01). IFNβ therapy, age, and disability
scores appeared unrelated with the B cell cytokine pro-
duction (data not shown). On the other hand, HCMV(−)
PMS displayed greater IL-6 and TNFα production as com-
pared to HCMV(+) PMS and HCMV(−) RRMS patients,
contrasting with comparable values of cytokine produc-
tion in HCMV(+) cases (Fig. 4c). These results suggest
that HCMV infection in PMS patients may decrease the
production of proinflammatory cytokines by B cells.
Fig. 1 Gating strategy for B cell subset analysis. Peripheral blood mononuclear cells were gated based on forward (FSC) and side scatter (SSC) (a).
After exclusion of DAPI(+) dead cells (b) and selection of CD45(+) lymphocytes (c), CD19+ B cell subsets (d) were defined as plasmablasts-plasma
cells (PB-PC: CD38hiCD10−) and transitional (TB: CD38hiCD10+) (e), gating in the CD38lowCD10− B cells (f) to define naive (NB: CD38low/negCD10
−IgD+CD27−), unswitched memory (UMB: CD38low/negCD10−IgD+CD27+), switched memory (SMB: CD38low/negCD10−IgD−CD27+), and double
negative (DN: CD38low/negCD10−IgD−CD27−). A representative case is illustrated in the figure, showing proportions of B cell subsets
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Discussion
In the present study, we provide data supporting that
HCMV infection alters the phenotypic and function of B
cells in MS, modulating the influence of IFNβ and redu-
cing the proinflammatory B cell profile. These observa-
tions may contribute to understand the putative
influence of this viral infection in MS, as suggested by
previous studies describing a low risk for MS in HCMV
seropositive cases [5, 6]. Although an epiphenomenon
linked to the exposure to other environmental factors
could not be excluded in the light of these observations,
putative mechanisms of heterologous immunity between
Table 1 Demographic and clinical characteristics of MS patients and controls
HC (n = 30) RRMS (n = 55) PMS (n = 18) p value, HC vs MS p value, RRMS vs PMS p value, RRMS vs HC
Age, years (mean ± SD) 41.1 ± 11.4 44.7 ± 12.1 60.1 ± 8.0 < 0.01 < 0.01 0.190
Female sex, n (%) 18 (60.0%) 31 (56.40%) 11 (61.10%) 0.498 0.914 0.173
HCMV(+) serology, n (%) 23 (76.7%) 35 (63.6%) 11 (61.1%) 0.133 0.400 0.093
EBV(+) serology, n (%) 24 (85.7%) 54 (98.2%) 17 (94.4%) < 0.05 0.075 < 0.05
MS duration (years) – 10.9 (5.5–16.0) 22.6 (13.9–33.3) – < 0.01 –
EDSS – 2.0 (1.0–3.0) 6.0 (4.4–7.0) – < 0.01 –
MSSS – 2.08 (1.01–4.17) 6.74 (3.74–7.46) – < 0.01 –
2y-RR – 0.0 (0.0–1.0) 0.0 (0.0–0.0) – < 0.01 –
ARR – 0.31 (0.17–0.57) 0.0 (0–0.13) – < 0.01 –
DMT None – 27 18 < 0.01 –
IFNβ – 23 0
GA – 5 0
Values are expressed as mean ± SD for parametric variables and as median (interquartile range) for nonparametric variables
HC healthy controls, RRMS relapsing-remitting MS, PMS progressive MS, HCMV human cytomegalovirus, EBV Epstein-Barr virus, EDSS expanded disability status
scale, MSSS Multiple Sclerosis Severity Score, 2y-RR relapse rate in the previous 2 years, ARR annualized relapse rate, DMT disease-modifying therapy, IFNβ
interferon-β, GA glatiramer acetate
Fig. 2 B cell subsets in controls and untreated MS patients according to clinical form and HCMV. a Percentages of B cell subsets within total B
cells (CD19+) in healthy controls (HC) and MS patients classified based on clinical form. b HC and MS patients according to HCMV serostatus.
RRMS: relapsing-remitting MS; PMS: progressive MS; PB-PC: plasmablasts-plasma cells; TB: transitional B cells; NB: naive B cells; UMB: unswitched
memory B cells; SMB: memory switched B cells, DN: double negative B cells. p values: *< 0.05, ***< 0.001
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viruses [13–15] and HCMV-induced modifications on
the immune system may be implicated in the effect of
HCMV on MS [7, 8, 16, 17]. In this regard, HCMV has
been described as an environmental factor inducing
striking effects on the immune system [7]. Nevertheless,
in contrast to the well-known role of HCMV as a driving
force behind the expansion of late-differentiated T lym-
phocytes [8, 18] and adaptive NK cells [9], the influence
of chronic HCMV infection on B cells is minor and
barely evaluated in previous studies.
B cells have been implicated in MS pathogenesis, with
a special relevance of the memory subset [2, 19]. Of
note, no HCMV-related differences in B cell subsets be-
tween controls and MS patients were found in our study.
However, an influence of the viral infection on the B cell
subset distribution, namely the proportions of NB and
SMB, was perceived when MS form was considered, with
an opposite effect in RRMS as compared to PMS pa-
tients. The reduced proportions of memory B cells ob-
served in HCMV(+) RRMS appear consistent with a
protective effect of the viral infection in MS described in
previous studies [5, 6]. Intriguingly, no influence of
HCMV was detected in the B cell subset distribution in
controls, in line with previous reports of minor HCMV-
induced modifications in the B cell compartment as
compared to T cells [18]. In this regard, HCMV-related
differences in B cell subsets and the functional profile
observed in our MS patients appeared uncoupled to
markers of terminal differentiation of T cells and expan-
sion of adaptive NKG2C+ NK cells (data not shown),
Fig. 3 Impact of HCMV on the B cell compartment in IFNβ-treated MS patients. a B cell subsets in untreated (n = 27), IFNβ-treated (n = 23), and
glatiramer-acetate-treated (n = 5) RRMS patients. b Untreated and IFNβ-treated MS patients classified based on HCMV serostatus. PB-PC:
plasmablasts-plasma cells; TB: transitional B cells; NB: naive B cells; UMB: unswitched memory B cells; SMB: memory switched B cells; and DN:
double negative B cells. p values: *< 0.05, **< 0.01, ***< 0.001, ****< 0.0001
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suggesting specific changes on the B cell compartment
induced by HCMV in the setting of MS.
Of note, the shift in the B cell subset distribution associ-
ated with HCMV in our untreated MS patients was rem-
iniscent of the impact of IFNβ therapy in HCMV
seronegative RRMS patients, an effect that might be hypo-
thetically related with interferon-signaling pathways in-
duced by persistent HCMV infection [20]. In addition, the
previously described increase of TB cells associated with
IFNβ [12] was only observed in HCMV(+) RRMS patients.
In view of the implications of B cells in the mechanism of
action of this cytokine [21], it is reasonable to hypothesize
that HCMV infection in MS patients may modulate the
influence of IFNβ on B cell differentiation.
B cells in MS have been shown to display a pro-
inflammatory cytokine profile [22, 23], which was also
Fig. 4 B cell cytokine production in controls and MS patients. a Representative cases illustrating the gating strategy and staining of pro-
inflammatory (GM-CSF, IL-6, TNFα) and anti-inflammatory cytokines (IL-10) in B cells in resting conditions and stimulated using CpG and PMA/
ionomycin. b B cell cytokine production in controls and MS patients according to MS clinical form. c Impact of HCMV on B cell cytokine
production in controls and MS patients classified based on clinical form. p values: *< 0.05, **< 0.01, ***< 0.001
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related with MS clinical form when B cells from CSF
were evaluated in PMS cases [24]. In our study, B cells
from HCMV(−) PMS patients displayed an enhanced
pro-inflammatory profile as compared to HCMV(+)
PMS cases, independently of other clinical variables. Al-
though limited by the reduced sample size of PMS pa-
tients evaluated, these results suggest that persistent
HCMV infection may reduce the inflammatory profile of
B cells in MS, in line with previous reports describing
differences in IL-10 production by B cells from monozy-
gotic healthy twins discordant for HCMV [7].
Conclusions
Altogether, our study supports that HCMV infection
modulates the distribution of B cell subsets and the
IFNβ response in MS patients, and associated with a re-
duced pro-inflammatory cytokine profile in PMS, thus
providing mechanistic insights on the putative beneficial
influence of HCMV in MS. Further studies are required
to assess whether HCMV may also modulate the im-
munological response to other MS therapies targeting B
cells [19, 25].
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